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628 S100A8/A9-MCAM-ETV4 axis induces breast cancer aggressiveness Chen et al. Neoplasia Vol. 21, No. 7, 2019Abstract
Metastatic breast cancer is the leading cause of cancer-associated death in women. The progression of this fatal
disease is associated with inflammatory responses that promote cancer cell growth and dissemination, eventually
leading to a reduction of overall survival. However, the mechanism(s) of the inflammation-boosted cancer
progression remains unclear. In this study, we found for the first time that an extracellular cytokine, S100A8/A9,
accelerates breast cancer growth and metastasis upon binding to a cell surface receptor, melanoma cell adhesion
molecule (MCAM). Our molecular analyses revealed an important role of ETS translocation variant 4 (ETV4), which
is significantly activated in the region downstream of MCAM upon S100A8/A9 stimulation, in breast cancer
progression in vitro as well as in vivo. The MCAM-mediated activation of ETV4 induced a mobile phenotype called
epithelial-mesenchymal transition (EMT) in cells, since we found that ETV4 transcriptionally upregulates ZEB1, a
strong EMT inducer, at a very high level. In contrast, downregulation of either MCAM or ETV4 repressed EMT,
resulting in greatly weakened tumor growth and lung metastasis. Overall, our results revealed that ETV4 is a novel
transcription factor regulated by the S100A8/A9-MCAM axis, which leads to EMT through ZEB1 and thereby to
metastasis in breast cancer cells. Thus, therapeutic strategies based on our findings might improve patient
outcomes.
Neoplasia (2019) 21, 627–640ca
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etastatic breast cancer classified as stage IV is the most serious
ncer-related disease in women. More than 90% of such patients die
metastasis, a process by which cancer cells depart from their tumor
origin, spread systemically, and colonize at distant organs [1]. Even
ith the current advanced therapies, it is difficult to effectively treat
age IV breast cancer, and the establishment of an effective inhibitory
eatment for breast cancer metastasis is needed. Elucidation of the
mplex mechanisms of breast cancer metastasis at the molecular level
needed for the establishment of such treatment.
Breast cancer cells seem to prefer the lung, liver, bone and brain as
eir metastatic sites. This organ-tropic metastasis is known as the
eed and soil” theory, and was first proposed by Paget et al. [2]. As to
e molecular-level mechanisms underpinning the theory, accumu-
ting evidence has revealed that cancer-mediated S100A8/A9 in the
ng plays a critical role in lung tropic metastasis and the subsequent
owth of cancer cells in the lung. In addition, Eisenblaetter et al.
cently reported that the process by which extracellular S100A8/A9
increased in the lung is distant cancer-mediated enrichment of a
cl2 chemokine and CCR2highCX3CL1low monocyte population,
d subsequent interaction of ligand Ccl2 with its receptor CCR2 in
e abundant monocytes in the breast cancer-bearing mouse lung [3].
hat process leads to an increase in immunosuppressive Treg cells,
d eventually to the formation of a pre-metastatic niche in the lung,
hich is designated as the “soil” in the “seed and soil” model.
iratsuka et al. clearly demonstrated in a melanoma lung metastasis
odel that lung S100A8/A9 functions as a strong chemokine to
tract distant cancer cells through its receptor toll-like receptor 4
LR4) [4]. However, the receptors of S100A8/A9 are not restricted
TLR4. The receptor for advanced glycation endproducts (RAGE)
so acts as an S100A8/A9 receptor. Moreover, in addition to TLR4
d RAGE, we previously revealed the presence of other importantndidate receptors, MCAM, ALCAM, EMMPRIN and NPTN
soforms α and β), which we collectively named the S100 soil sensor
ceptors (SSSRs). Hence, S100A8/A9 plays a crucial role in lung
opic cancer metastasis by helping to establish an immunosuppres-
ve metastatic niche to which it then attracts remote cancer cells by
imulating various receptors on the cancer cell surface as chemokine-
e ligands.
Here, we attempt to determine the main receptors functioning in
etastatic breast cancer cells. Among the receptors mentioned above,
e recently found that MCAM was remarkably overexpressed in
etastatic breast cancer cells, which was also supported by the
evious reports [5–7]. However, the MCAM downstream signal
on S100A8/A9 binding in breast cancer cells that produces the
iving force for distant metastasis has remained unclear. In this
udy, we therefore aimed to clarify that mechanism(s) at the
olecular level.
esults
ighly Up-Regulated Cellular Motility, Invasiveness and
CAM Expression in Triple-Negative Malignant MDA-MB-
31 Cells
Figure 1, A and B show that MDA-MB-231 cells had the highest
vels of activity for both migration and invasion among the breast
ncer cells we examined. We previously reported that the S100A8/
9-SSSRs axis plays an important role in these cellular behaviors, so
our present experiments we attempted to determine the expression
ofile of the SSSRs in these breast cancer cell lines [8–10].
uantitative real-time PCR analysis showed that MCAM expression
as highly elevated in MDA-MB-231 cells in a specific manner
igure 1C). By using publicly available data sets (http://watson.
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Figure 1. Highly upregulated cellular motility, invasiveness and MCAM expression in triple-negative malignant MDA-MB-231 cells. A and
B, Cellular migration and invasion were monitored according to the Boyden chamber method. The indicated cells were placed on the top
surface of non-sealed inserts (A) or Matrigel-sealed inserts (B). Quantified results are displayed in the upper panel and representative
images of migrating cells are shown in the bottom panel. C, Quantitative real-time PCR analysis was carried out in the indicated cells for
RAGE, MCAM, ALCAM, EMMPPRIN, NPTNα, NPTNβ, S100A8 and S100A9 genes. The relative expression level of each sample is shown
after calibration with the level of TBP (a suitable housekeeping gene). Data are means ± SD, *P b .05, **P b .01 and ***P b .001. N.D.: not
detected.
Neoplasia Vol. 21, No. 7, 2019 S100A8/A9-MCAM-ETV4 axis induces breast cancer aggressiveness Chen et al. 629mpbio.iupui.edu/chirayu/proggene/database/index.php), we found
at the rates of both overall survival and metastasis-free survival were
gnificantly lower in patients with MCAM-abundant tumors than in
tients with MCAM-scant tumors (Figure S1A and Figure S1B).
hese results imply an unusual role of MCAM in the metastatic
gressiveness of breast cancer diseases. Accumulating evidence has
dicated that MCAM overexpression is involved in tumorigenesis
d subsequent aggressive progression in not only breast cancer cellst also various cancer species such as melanoma [11], hepatocellular
rcinoma [12] and small-cell lung cancer (SCLC) [13] and that
undant MCAM in tumors is linked to poor survival of these tumor-
aring patients. We previously demonstrated that MCAM is highly
creased in metastatic melanoma and functions as an S100A8/A9
ceptor. The binding of S100A8/A9 derived from the remote lung
gion activates the melanoma and attracts melanoma cells to the
00A8/A9-enriched lung area through the cell surface MCAM
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Figure 2. Significance of the S100A8/A9-MCAM axis in cancer mortality. A, MDA-MB-231 cells were transfected with either MCAM
siRNAs (siMCAM #1, siMCAM #2) or a negative control scrambled siRNA (siCont.) and then assessed for their migration abilities in
response to extracellular S100A8/A9 (100 ng/ml). B, MCF-7-derived stable sublines, GFP #1, MCAM #1 and MCAM #6 (see Figure S3),
were assessed for their migration abilities in response to extracellular S100A8/A9 (100 ng/ml). C, MCF-7-derived stable sublines, GFP #1,
MCAM #1 and MCAM+ETV4 ΔDNA-BD #1 (see Figure S3), were assessed for their migration abilities in response to extracellular
S100A8/A9 (100 ng/ml) in the presence or absence of a decoy exMCAM-Fc recombinant protein (1000 ng/ml). Data are means ± SD, N.S.:
not significant, *P b .05 and ***P b .001.
630 S100A8/A9-MCAM-ETV4 axis induces breast cancer aggressiveness Chen et al. Neoplasia Vol. 21, No. 7, 2019nsor, resulting in melanoma lung tropic metastasis [10]. Hence, a
milar mechanism may be adopted in melanoma and other breast
ncer cells.
gnificance of the S100A8/A9-MCAM Axis in Cancer Mortality
We next attempted to determine the significance of the S100A8/
9-MCAM axis in the metastatic mortality of MDA-MB-231 cells.
e used the siRNA technique to attenuate the intrinsic MCAM
nction. We confirmed the knockdown effects of the siRNAs used
d we found that the efficacy of siMCAM #1 was higher than that of
MCAM #2 (Figure S2). As shown in Figure 2A, we found that the
o siRNAs induced downregulation of the migration ability of
DA-MB-231 cells not only under the basal condition but also in
sponse to stimulation with S100A8/A9. Conversely, we then
aluated the effect of MCAM overexpression. Since the expression of
dogenous MCAM in MCF-7 cells is relatively low, we forced
CF-7 cells to express foreign MCAM at a higher level in a sustained
anner, resulting in the establishment of MCF-7-derived stable
blines (Figure S3). We randomly chose four GFP (Figure S3A, left),
ur MCAM (Figure S3B, top left), and four MCAM+ETV4 ΔDNA-D clones (Figure S3B, top right). All of the selected GFP clones
owed lower migration activity (Figure S3A, right), while the
CAM clones showed a tendency for increased basal migration
ility (Figure S3B, bottom). The migration ability was further
regulated by S100A8/A9 stimulation in MCAM clones (#1 and
) but not in the GFP clone (#1) (Figure 2B). To further understand
e importance of S100A8/A9-MCAM interaction in breast cancer
igration, we treated the MCAM-overexpressed MCF-7 cells with an
MCAM-Fc decoy that prevents interaction between S100A8/A9
d cellular MCAM in a ligand S100A8/A9-absorptive manner. As
pected, the decoy almost completely abrogated the elevation of
00A8/A9-mediated migration (Figure 2C).
entification of the S100A8/A9-MCAM-ETV4-ZEB1 Pathway
Our previous search using protein/DNA array I (Thermo Fisher
ientific) for transcription factors that could generate the metastatic
iving force and could be regulated by anMCAM downstream signal
ovided four potential candidates, ETS, GATA, NFI and PPAR
upplementary Table S1, marked in red color) among the MCAM-
duced several transcription factors [14]. Among these, we focused
on
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Neoplasia Vol. 21, No. 7, 2019 S100A8/A9-MCAM-ETV4 axis induces breast cancer aggressiveness Chen et al. 631the significance of ETS, since an ETS decoy oligonucleotide in the
ur candidates’ decoys (Supplementary Table S2) had a preventive
fect on the migration activity in MDA-MB-231 cells (Figure S4A).
hat spurred us to try to identify the ETS protein producing the
etastatic force in breast cancer cells from ETS family proteins.
uantitative real-time PCR analysis showed that ETV1, ETV4,
TV5 and ELK3 were expressed in MDA-MB-231 cells at very highA
B
D
gure 3. Identification of the S100A8/A9-MCAM-ETV4-ZEB1 pathway. A
gular time intervals, and the nuclei of the treated cells were collected a
arify the ETV4-mediated band, an ETV4 antibody was used for a super
CAM dn plasmid, siCont., or siMCAM #1 and then treated with S100
alysis for the treated cell nuclear extracts (right). B, A luciferase (luc)
lls after transfection with the reporter vector in combination with a con
, Quantitative real-time PCR analysis was carried out in the indicated
mple is shown after calibration with the TBP value. D, MDA-MB-231 ce
t expression vector. The transfected cells were lysed and subjected to
eans ± SD, ***P b .001.vels and in a cell-specific manner (Figure S4B). When we forced
CF-7 cells to overexpress these proteins, we found that the
pression of ETV1, ETV4 and ETV5, but not that of ELK3,
sulted in the acquisition of much higher cell-migration activity
igure S5A). Since epithelial-mesenchymal transition (EMT)
cilitates metastasis of cancer cells, we investigated the induction of
MT markers by ETV1, ETV4, ETV5 and ELK3 transcriptionC
, MDA-MB-231 cells were treated with S100A8/A9 (100 ng/ml) for
t different time points, lysed and subjected to EMSA analysis. To
shift experiment (left). MDA-MB-231 cells were transfected with
A8/A9 (100 ng/ml). ETV4 activity was monitored again by EMSA
-based ZEB1 promoter reporter assay was performed in HEK293
trol empty vector, ETV4 wt or ETV4 ΔDNA-BD expression vector.
cells for the ZEB-1 gene. The relative expression level of each
lls were transfected with GFP, MCAM dn, siMCAM#1 or MCAM
WB analysis to examine endogenous ZEB1 conditions. Data are
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632 S100A8/A9-MCAM-ETV4 axis induces breast cancer aggressiveness Chen et al. Neoplasia Vol. 21, No. 7, 2019ctors. As shown in Figure S5B, we found that ETV4 alone has the
ility to induce expression of several EMT markers, including N-
dherin, TWIST1 and ZEB1, at the highest levels. To determine
hich EMTmarkers are regulated by ETV4 with the help of MCAM,
e transfected MCF-7 cells again with an empty vector, MCAM,
TV4 wt or ETV4 ΔDNA-BD vector (deletion of C-terminal DNA-
nding domain: 342-484 aa). This approach showed that ZEB1 is
e most suitable EMT molecule for regulation by MCAM and
bsequent ETV4 activation (Figure S6A). ETV4, also called E1AF
PEA3, has been shown to be closely involved in breast cancer
ogression [15]. Due to its protein function as a transcription factor,
TV4 has many target genes associated with cancer promotion. Jiand
al. reported that ETV4 enhances cell cycle progression via the
regulation of cyclin D3 transcription [16]. MMP2, the renowned
vasion-associated matrix metalloprotease, is also positively regulated
ETV4 [17]. We also newly found that ZEB1, a strong EMT
ducer, is a potential target gene of ETV4.
To further clarify S100A8/A9-MCAM-ETV4-ZEB1, the signaling
thway that appeared to be responsible for the acquisition of
etastatic force by breast cancer cells, we first performed an
ectrophoretic mobility shift assay (EMSA) to detect the activation
ETV4 through MCAM upon S100A8/A9 binding. EMSA analysis
vealed time-dependent activation of intrinsic ETV4 after stimula-
on with S100A8/A9 (Figure 3A, left). In addition, the S100A8/A9-
ediated activation of ETV4 was remarkably downregulated by
ocedures for the prevention of endogenous MCAM expression by
ing either forced expression of MCAM dn (deletion of cytoplasmic
il: D 584-646 aa) or siMCAM#1 transduction into cells (Figure 3A,
ght). The activation of ETV4 is closely linked to MCAM-mediated
evation of migration ability, since ETV4 ΔDNA-BD overexpression
fectively reduced cellular migration even under an abundant
CAM condition (Figure S6B). These results indicate that ETV4
positively regulated by MCAM via S100A8/A9 binding and that
ch activated ETV4 plays a critical role in the enhancement of
llular migration. Thus, ETV4-mediated cancer migration may be a
itical step for breast cancer metastasis and may greatly affect patient
rvival. Yuan et al. reported that a highly elevated level of ETV4
otein in triple-negative breast cancer was associated with a high risk
distant metastasis in their patients [18]. In addition, our web-based
arch (http://watson.compbio.iupui.edu/chirayu/proggene/
tabase/index.php) of the literature indicated a marked reduction
both overall (Figure S7A) and relapse-free (Figure S7B) survival of
east cancer patients with elevated levels of ETV4 protein.
At this point, we need to address how ETV4 is activated upon
CAM-S100A8/A9 binding. It is known that ERK1/2-mediated
osphorylation of ETV4 has a crucial role in the transcriptional
tivation of ETV4. We also found that ERK1/2 is highly activated
MCAM stimulation with S100A8/A9 (Figure S8). We therefore
eculate that ERK1/2 activation under MCAM is at least partly
sponsible for triggering the ETV4 activation.
Our next interest was in ZEB1 activation through the S100A8/A9-
CAM-ETV4 axis. ETV4 and ZEB1 have long been independently
cognized for their unusual roles in cancer aggressiveness [19,20].
owever, it has not been determined whether their roles are linked in
me way. To determine whether ETV4 can lead to changes in the
pression of target genes, we performed a ZEB1 promoter reporter
say. The results showed that the ETV4 wt, but not ETV4 ΔDNA-
D, induced promoter activation of ZEB1 at a much higher level
an that induced by the control empty vector (Figure 3B).terestingly, ZEB1 expression was markedly elevated in MDA-
B-231 cells (Figure 3C), which also showed critical expression levels
intrinsic MCAM (Figure 1C) and ETV4 (Figure S4B). These
olecular patterns were also linked to cellular metastatic phenotypes
igure 1, A and B). When we inhibited MCAM function using three
fferent methods—i.e., MCAM dn-forced expression, siMCAM
ansduction and MCAM cyt-forced expression (a competitor of the
CAM signal)—we found that all three procedures inhibited ZEB1
pression in MDA-MB-231 cells (Fig. 3D). The identified pathway
likely to universally arise in triple-negative breast cancer cells. In this
e of investigation, it also turned out that forced expression of ETV4
DNA-BD effectively mitigated the S100A8/A9-induced migration
another triple-negative breast cancer cell line (Figure S9A).
oncomitant with this, the S100A8/A9-induced upregulation of
TV4 activity (Figure S9B) and subsequent ZEB1 induction (Figure
C) were both pronouncedly reduced by the forced expression of
TV4 ΔDNA-BD as well as MCAM knock down. Thus, we revealed
r the first time that the MCAM-ETV4 signal is a crucial regulator of
e ZEB1 gene that consistently occurs in triple-negative breast
ncer cells.
MT Phenotype Expression Through the MCAM-ETV4 Axis
In order to investigate whether a biological connection truly exists
tween the identified pathway and the EMT phenomenon, we
rther established MCAM+ETV4 ΔDNA-BD-overexpressed stable
blines (#1, #2, #3 and #6) from MCF-7 cells (Figure S3B). The
ones all showed relatively low levels of migration activity even at a
gher level of foreign MCAM expression (Figure S3B, right)
mpared to those of the clones overexpressing MCAM alone (Figure
B, left). When we closely examined the appearance of the
dividual cells in these established cell clones (GFP #1, MCAM
, and MCAM+ETV4 ΔDNA-BD #1), we found that only the
CAM #1 clone was sparsely distributed in a culture space with a
esenchymal phenotype, while ETV4 ΔDNA-BD (MCAM+ETV4
DNA-BD #1) never showed this activity, resulting in a phenotype
milar to that of the GFP #1 clone, which shows an epithelial
enotype with tightly attached together (Figure 4A). We observed
ese same characteristics in all the clones that we established (data
t shown). Since E-cadherin is a reliable epithelial marker that
nctions in cell-cell adhesion, we further examined the E-cadherin
vel in each of the clones as indicated in Figure 4A. In a reflection of
e cellular phenotypes, we found that MCAM overexpression
CAM #1 clone) reduced E-cadherin expression and that ETV4
DNA-BD (MCAM+ETV4 ΔDNA-BD #1 clone) rescued E-
dherin from its own MCAM-mediated reduction (Figure 4, B
d C). These results indicated that the S100A8/A9-MCAM-ETV4-
EB1 pathway plays a major role in breast cancer migration
ncomitant with EMT, which may contribute to breast cancer
alignancy. In fact, Jang et al. reported that increased expression of
EB1 was correlated with abundant MCAM in triple-negative breast
ncer cells, and was associated with poor clinical outcomes in
tients with triple-negative breast cancer [21].
TV4 is Essential for the Growth and Metastasis of Breast
ancer In Vivo
The biological role of ETV4 in breast cancer progression was
rther assessed in an in vivo setting using an orthotopic xenograft
odel (Figure 5). Overexpression of the ETV4 wt in MDA-MB-231
lls (ETV4 wt #1 clone) significantly promoted tumor growth
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Figure 4. EMT phenotype expression through the MCAM-ETV4 axis. A, Cell distributions in the MCF-7-derived clones, GFP #1, MCAM #1 and
MCAM+ETV4 ΔDNA-BD #1 (see Figure S3), were monitored for their GFP expression by using a fluorescence microscope. B, The cell sublines
were collected, lysed, andsubjected toWBanalysis to detect endogenousE-cadherin levels (left). Thequantificationof E-cadherin band intensities
is shown after calibration with b-actin bands as an internal control. C, Immunofluorescence staining was carried out to detect E-cadherin.
Neoplasia Vol. 21, No. 7, 2019 S100A8/A9-MCAM-ETV4 axis induces breast cancer aggressiveness Chen et al. 633igure 5, A and B) as evidenced by the larger tumor weight
igure 5C) and faster growth kinetics (Figure 5D) compared to the
FP control group (GFP #1 clone), who were treated by mammary
t pad injection (Figure 5). These results support the potential
sitive correlation between ETV4 expression and worse clinical
tcomes in breast cancer patients (Figure S7). On the other hand,
TV4 ΔDNA-BD (ETV4 ΔDNA-BD #1 clone) had no positive
fect on tumor progression. To investigate whether ETV4 confers an
creased metastatic potential other than tumor growth, we
rformed tail vein injection of MDA-MB-231 stable clones and
sessed their lung colonization. Two months after injection, both
acro images (Figure 5E, top panels) and hematoxylin-eosin staining
igure 5E, middle and bottom panels) of the dissected lungs showed
much larger number of metastatic nodules in the ETV4 wt groupmpared with the GFP control or ETV4 ΔDNA-BD group (Figure
). These results indicate that ETV4 plays an important role in both
mor growth and metastasis in breast cancers. Overall, the results
pport the idea that the newly identified axis S100A8/A9-MCAM-
TV4 greatly contributes to the progression of breast cancers by
ducing ETV4 target genes, including ZEB1, that enhance tumor
owth and metastasis, and this axis may be linked to the poor survival
patients with breast cancers in which MCAM (Figure S1) and
TV4 (Figure S7) are jointly produced.
TV4 Leads to a Global Reprogramming of Gene Expression
Finally, due to the critical function of ETV4 as a transcription
ctor in tumor progression, we attempted to gather information on
identified genes targeted by ETV4 (other than ZEB1) in order to
be
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Figure 5. ETV4 is essential for growth and metastasis of breast cancer in vivo. A, Representative imaging of mice bearing MDA-MB-231
stable clones (GFP #1, ETV4 wt #1 and ETV4 ΔDNA-BD #1) after mammary fat pad injection. n=5. B, Photograph of the dissected tumor.
C, Weight of the dissected tumor. D, A tumor growth curve was established after injection, and the tumor diameter was measured every
week. E, Each representative clone (5 x 105 cells) was injected into mice through the tail vein. Lung metastatic nodules were quantified
after 2 months. Lung tumor nodules were observed macroscopically (top) and their sections were also observed by H&E staining (middle
and bottom). n=5. F, Number of lung colonies in E. Data are means ± SD, N.S: not significant, *P b .05, **P b .01 and ***P b .001.
634 S100A8/A9-MCAM-ETV4 axis induces breast cancer aggressiveness Chen et al. Neoplasia Vol. 21, No. 7, 2019tter understand the cancer-associated role of ETV4, which may also
ntribute to breast cancer aggressiveness coordinately with ZEB1.
o identify other MCAM-ETV4 target genes relevant to breast
ncer aggressiveness, we carried out a comprehensive analysis of gene
pression in an MCF-7-derived stable clone, MCAM+ETV4
DNA-BD #1, in comparison to that in the MCAM #1 clone
igure 6). By this approach, we found that genes whose expressions
ere either increased or decreased in ETV4-preventive cells (MCAM
TV4 ΔDNA-BD #1) were associated with cancer disease
igure 6A, marked in red color), and more often associated with
etabolic disease than with any other conditions (Figure 6A). When
e focused on the genes for which expression was downregulated byTV4 ΔDNA-BD overexpression, we found that many genes were
sociated with inflammation and glucose metabolism (Figure 6B).
nce cancer cells frequently change their own metabolic pathway
om aerobic to anabolic using the glycolytic system in response to
aracteristic alterations of the cancer-surrounding environments
2], ETV4 may play a significant role in the regulation of cancer
etabolisms. Analysis of the altered genes in expression on the
EGG pathway also yielded the important finding that a number of
ncer-related pathways, including NFκB and Akt, and leading to
all lung cancer and viral carcinogenesis, were all associated with
TV4 (Figure 6C). Thus, the reason for the critical role of ETV4 in
east cancer progression may be that ETV4 induces a large number
A D
B
C
E
Figure 6. RNA-seq analysis. A, Functional enrichment analysis (P b .05) was performed for protein-coding RNAs in GAD_DISEASE_CLASS with
upregulated anddownregulatedgenes in theMCF-7-derivedMCAM+ETV4ΔDNA-BD#1clone in comparison to those in theMCAM#1clone. B and
C, For the downregulated genes, functional enrichment analysis (P b .05) was also performed in GO (B) and KEGG (C) analysis. D, Heat maps are
displayed for the selected genes that are upregulated and downregulated in the cancer category of the disease clustering as indicated in (A). These
analyseswereperformedusing thedatabase for annotation, visualizationand integrateddiscovery (DAVID) v6.8 (http://david.ncifcr.gov/). E,Quantitative
real-time PCR analysis was carried out in the indicated cells for the genes shown in (D). The relative expression level of each sample is shown after
calibration with the TBP (a suitable housekeeping gene) value. Data are means ± SD, *P b .05, **P b .01 and ***P b .001. ND: not detected.
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Figure 7. Graphical schematic of breast cancer metastasis based
on the S100A8/A9-MCAM-ETV4-ZEB1 axis.
636 S100A8/A9-MCAM-ETV4 axis induces breast cancer aggressiveness Chen et al. Neoplasia Vol. 21, No. 7, 2019cancer-associated molecules (Figure 6D and 6E) and establishes the
thways involving them, and these pathways in turn may function
ordinately.
iscussion
reast cancer is a major cause of cancer-related mortality in women
orldwide. The vast majority of deaths are attributed to metastasis.
he key factors in breast cancer tumorigenesis and metastasis are
tokines in the tumor microenvironment. In normal tissue,
tokines have a growth inhibitory role in the epithelium [23].
owever, in breast cancer, through a series of genetic and epigenetic
anges, and autocrine and paracrine signals, the tumor microenvi-
nment is activated, losing its protective effects and becoming the
ajor factor in the initiation and the progression of the tumors
4–27]. In our study, we demonstrated that the cytokine S100A8/
9 is a novel key regulator that binds to MCAM, leading to
gnificant activation of the oncogenetic transcription factor ETV4,
d eventually promoting activation of the EMT marker ZEB1. We
und that induction of a remarkable level of ETV4 was a cause of the
set of breast cancer dissemination and subsequent distant lung
etastasis.
MCAM (or CD146, Mel-CAM, MUC18, S-endo1), also known
the melanoma cell adhesion molecule, was first described in
alignant melanomas, where it was expressed at high levels and found
be associated with poor prognosis [28,29]. More recently, high-
vel expression of MCAM has been associated with the metastatic
ogression in hepatocellular carcinoma [12,30] and ovarian cancer
1]. The presence of several protein kinase recognition motifs in the
toplasmic domain suggests the involvement of MCAM in
wnstream cell signaling [32]. In a recent study, we showed that
e of the mitogen-activated protein kinase kinase kinases
AP3Ks), which directly binds to MCAM, plays a key role in the
tivation of malignant melanoma metastasis. This finding revealed a
stinctive function of MCAM other than adhesion. To determine
e mechanism(s) by which MCAMmodulates metastasis, we applied
ree different techniques to inhibit the function of MCAM. We
und that each of these inactivated forms of MCAM—i.e., MCAM
activated by transduction with a dominant negative vector, siRNA
MCAM cytoplasmic tail vector—abrogated the S100A8/A9-
duced expression of ETV4 (Figure 3A, right), probably in an
RK1/2-dependent manner (Figure S8). Since robust ERK1/2
tivation was observed in S100A8/A9-MCAM-induced breast
ncer metastasis, we postulated that ETV4, a positive regulator of
RK/MAPK, is involved in the migration of cancer cells. This
eculation was also supported by the results of a recent study.
amely, Fung reported that a novel signal pathway, ERK-MAPK-
TV4-MMP-E-cadherin, drove the malignance of esophageal
rcinoma [33]. Consistent with their findings, we clearly demon-
rated that MCAM exacerbated breast cancer migration, and this
fect was associated with enhanced ERK1/2-ETV4 activation.
Our observations indicate that ETV4 transcription factor that is
sitively regulated by MCAM may be a key nuclear effector of
cogenic MAPK signaling. Indeed, the results of a prior study
ggested that ETV4 may activate a RAS and MAPK transcriptional
ogram in the absence of the MAPK pathway [34]. ETV4 is known
be involved in events participating in tumor development and
ogression, indicating that ETV4 has a function similar to that of
CAM. In this study, we demonstrated that ETV4 is activated by
CAM, a conclusion that appears to be supported by the analogouserall survival of breast cancer patients with MCAM-activated ETV4
om public databases (Figure S1 and Figure S7). ETV4 is also known
be a significant mediator of tumorigenesis through the activation of
veral downstream pathways that are associated with migration,
vasion and stemness [35,36]. For instance, inhibition of ETV4 in
stric carcinoma and pancreatic carcinoma significantly impairs the
vasive capacity of cancer cells [20,37]. Our data demonstrated that
EB1 expression at the mRNA level is positively correlated with
TV4 expression levels and ectopic overexpression of the ETV4 wt in
DA-MB-231 cells further promoted their cancer progression in an
thotopic mouse model (Figure 5). As an epithelial-to-mesenchymal
ansition (EMT) marker, the importance of ZEB1 has been well
cumented. However, the role of EMT in activating metastasis has
cently been challenged [38,39], with the Snail and Twist EMT
anscription factors increasingly thought to play key roles in breast
d pancreatic cancer. In contrast, our results clearly described that
EB1 stimulates breast cancer lung metastasis based on ETV4
tivation.
One of the most striking consequences of our findings concerns the
itical function of ETV4. The regulatory potential of ETV4 is not
ited to effects on a few crucial downstream target genes but rather
ads to a global reprogramming of gene expression patterns, and
ntrols not only EMT but also other programs and pathways. The
sults of our RNA-seq analysis (Figure 6) brought many genes of
terest to our attention (Figure 6D). Next, therefore, we examined
e expression profiles of key genes in each of the clones (Figure 6E).
ue to the strong anti-apoptotic function of BCL2 and survival
nction of RELB, a component of NFκB, both BCL2 and RELB
ay confer the survival ability to breast cancer cells through ETV4.
or the acquisition of metastatic ability, it has long been recognized
at the Cxcl12 receptor, C-X-C chemokine receptor 4 (CXCR4),
omotes breast cancer cell metastasis to the lung. In addition, IL6ST,
K1 and JAK2 are also interesting, since these molecules play a
itical role in STAT3 activation. Accumulating evidence has
dicated that the transcription factor STAT3 promotes breast cancer
gressiveness [40]. The predicted ETV4-targeted genes, which are
sitively regulated by the MCAM-ETV4 pathway, may cooperate
ith ZEB1 to induce breast cancer progression. Further studies are
quired to determine the association between these molecules in the
CAM-ETV4 pathway and breast cancer progression.
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Neoplasia Vol. 21, No. 7, 2019 S100A8/A9-MCAM-ETV4 axis induces breast cancer aggressiveness Chen et al. 637Taken together, the results of our study revealed a critical role of
CAM in breast cancer upon S100A8/A9 binding extracellularly,
dicating an essential function of inflammatory cytokines in cancer-
sociated microenvironments. Downstream signaling analysis
owed that MCAM promotes activation of ETV4, which further
odulates ZEB1 and others transcriptionally (Figure 7). Inhibition of
is pathway would be a promising therapeutic alternative in breast
ncer treatment.
onclusions
ere we showed that the S100A8/A9-MCAM-mediated signal
thway leads to an aggressive metastasis of breast cancer to the
ng in a tumor-bearing mouse. That the identified molecules were
tivated one after another in response to MCAM stimulation via
00A8/A9 was a novel finding, and the revealed signaling pathway
owed that MCAM promotes activation of ETV4, which further
odulates ZEB1 (Figure 7). We hope that our findings will lead to a
tter understanding of the physiological and pathological mecha-
sms in breast cancer metastasis, and suppression of the identified
thway might be an effective approach for prevention of metastasis
targeting the S100A8/A9-MCAM axis in breast cancer and
obably other cancers.
aterials and Methods
ell Lines
The following cell lines were used in this study: HEK293T (a
man embryonic kidney cell line stably expressing the SV40 large T
tigen; RIKEN BioResource Center, Tsukuba, Japan), MCF-10A (a
n-tumorigenic human breast epithelial cell line; ATCC, Rockville,
D), MCF-7 (a human breast cancer cell line; ATCC), SK-BR-3 (a
man breast cancer cell line; ATCC), YMB-1-E (a human breast
ncer cell line; JCRB Cell Bank, Tokyo), and MDA-MB-231 (a
man breast cancer cell line; ATCC). MCF-10A cells were cultured
DMEM/Ham's F-12 (D/F) medium (Thermo Fisher Scientific,
altham, MA) supplemented with 100 ng/ml cholera toxin, 20 ng/
l epidermal growth factor (EGF), 0.01 mg/ml insulin, 500 ng/ml
drocortisone and 5% FBS (Intergen, Purchase, NY). HEK293T,
CF-7, SK-BR-3, YMB-1-E and MDA-MB-231 cells were all
ltivated in D/F medium (Thermo Fisher Scientific) supplemented
ith 10% FBS (Intergen).
ecombinant Proteins
Human S100A8/A9 recombinant protein was prepared from the
eeStyle 293 Expression System (Thermo Fisher Scientific) as
eviously reported [10]. The exMCAM-Fc decoy protein was
epared from its transduced CHO-S stable clone conditioned media.
he CHO clone was established by a convenient electroporation gene
livery method using an improved plasmid named pSAKA-1B [9]
sed on the pIDT-SMART (C-TSC) vector [41]. After collection of
e serum-free conditioned medium from large-scale culture of the
tablished CHO-S clone, exMCAM-Fc was purified by protein-G
finity chromatography according to the manufacturer’s instructions.
lasmids
The pIDT-SMART (C-TSC) vector, abbreviated as pCMViR-
SC, was used for temporal overexpression of foreign genes. The
NAs inserted into the vector were as follows: human cDNAs
coding MCAM, MCAM dn (deletion of cytoplasmic tail: D 584-
6 aa), MCAM cyt (cytoplasmic tail: 584-646 aa), ETS family genesTV1, ETV4, ETV5, ELK3), and ETV4 ΔDNA-BD (deletion of
-terminal DNA-binding domain: D 342-484 aa). MCAM, MCAM
and MCAM cyt were designed for expression as C-terminal
HA-6His-tagged forms. ETS family genes and ETV4 ΔDNA-BD
ere designed for expression as C-terminal 3xMyc-6His-tagged
rms. The cells were transiently transfected with the plasmid vectors
ing FuGENE-HD (Promega, Madison, WI).
To obtain stable transformants that show significantly high
pression levels of the transduced genes in a sustained manner, we
ed another improved vector based on pIDT-SMART (C-TSC),
med pSAKA-4B, which is useful for a broad range of human cell
es but not rodent CHO cells. MCAM-3xHA-6His and ETV4
DNA-BD -3xMyc-6His were inserted into pSAKA-4B [42]. A
ries of clones (see Figure S3) was established by a convenient
ectroporation gene delivery method and subsequent selection with
romycin at 20 μg/ml.
RNA
Human MCAM siRNA (#1, ID No. s8571; #2, ID No. s8572) and
ntrol siRNA (Silencer Negative control siRNA #1) were purchased
om Thermo Fisher Scientific. The siRNAs were transfected using
pofectamin RNAiMAX reagent (Thermo Fisher Scientific).
NA-seq Based Analysis
Total RNA was extracted from cells with ISOGEN (Nippon Gene,
okyo) according to the manufacturer’s instructions. The isolated
NA was subjected to RNA-seq-based analysis of gene expression
ioengineering Lab, Kanagawa, Japan).
uantitative Real-Time PCR
Real-time RT-PCR was performed in a LightCycler rapid thermal
cler system (ABI 7900HT; Applied Biosystems, Foster City, CA)
ing a LightCycler 480 SYBR Green I Master Kit (Roche
iagnostics, Indianapolis, IN) according to the manufacturer’s
structions. The forward and reverse primer pairs used (5’ to 3’)
e shown in Supplementary Table S3.
estern Blot Analysis
Western blotting was performed under conventional conditions.
he antibodies used were as follows: rabbit anti-ZEB1 antibody
roteintech Japan, Tokyo), mouse anti-E-cadherin antibody (BD
iosciences, Bedford, MA), mouse anti-HA tag antibody (Cell
gnaling Technology, Beverly, MA), mouse anti-Myc antibody (Cell
gnaling Technology) and mouse anti-human β-actin antibody
igma-Aldrich). The secondary antibody was horseradish peroxidase-
njugated anti-mouse or anti-rabbit IgG antibody (Cell Signaling
echnology).
uciferase Assay
The human ZEB1 (3391 bp with SacI and HindIII sites from the
anslation start site) promoter was amplified with genomic DNA from
epG2 cells by PCR and cloned into the luciferase reporter vector
L4.11 (Promega). The primers used to amplify the promoter were 5′-
aggataaaataagataaaatcagc-3′ and 5′-aaagccacatcagcaacagc-3′.
pGL4.11 carrying the human ZEB1 promoter and pGL4.74
coding Renilla luciferase regulated under the HSV-TK promoter as
internal control were transfected into HEK293T cells with
lyethyleneimine Max (Polyscience, Warrington, PA) as a transfec-
n reagent. For co-transfection, pCMViR-TSC vectors carrying
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638 S100A8/A9-MCAM-ETV4 axis induces breast cancer aggressiveness Chen et al. Neoplasia Vol. 21, No. 7, 2019TV4 expression plasmids (wt and ΔDNA-BD) were used for
onitoring the ZEB1 promoter. After 48 h, transfected cells were
easured using a Dual-Glo Luciferase Assay System (Promega).
lectrophoretic Mobility Shift Assay (EMSA)
Cell nuclear extracts were prepared according to the manufacturer’s
structions by using NE-PER nuclear and cytoplasmic extraction
agents (Thermo Fisher Scientific), and EMSA was performed using
LightShift Chemiluminescent EMSA kit (Thermo Fisher Scientif-
). A 5′-biotin-labeled double-stranded probe (forward: 5′-agtacCG-
AAGTaca-3′; reverse: 3′-tgtACTTCCGgtact-5′) was purchased
om Sigma-Aldrich. Rabbit anti-human PEA3/ETV4 antibody
ovus, Littleton, CO) was used for super shift analysis. After the
actions, all samples were fractionated by 7% PAGE and blotted
to a Biodyne B nylon membrane (Pall, Tokyo).
ell Migration and Invasion
Migration and invasion assays were performed by the Boyden
amber method. For the invasion assay, 8-μm pore filters set in
ranswell culture inserts (BD Biosciences) were coated with Matrigel.
ells were placed in the upper chamber in a low-serum medium, D/F
.5% FBS), and the lower chamber was filled with high-serum
edium, D/F (10% FBS), in the presence or absence of S100A8/A9
combinant protein (100 ng/ml). After 24 hours (for MDA-MB-231
lls) and after 48 hours (for MCF-7 cells), cells that had passed
rough the membrane were stained with hematoxylin eosin (H&E)
uto Pure Chemicals, Tokyo). Each transwell insert was micro-
opically imaged in five distinct regions at 10× in triplicate. The
mbers of cells that had migrated to the five distinct regions were
unted using the software (BZ-analysis application; Keyence) and
mmed as the total cell number.
nimal Experiments
Experimental protocols were approved by the Animal Experiment
ommittee of Okayama University (approval no. OKU-2014011). All
themouse procedures and euthanasia, including cell transplantations,
ere done painlessly or under anesthesia according to the strict
idelines of the Experimental Animal Committee of Okayama
niversity. To examine tumor metastasis in vivo, MDA-MB-231
lls and the clones from which they originated were used in animal
periments. The established clones (5x105 cells) were injected into the
ammary fad pads of Balb/c nude mice (Charles River Laboratories,
okohama, Japan) at the age of 6 weeks. Two months later, the mice
ere sacrificed and the tumors were dissected out and examined. As a
ngmetastasis model, 5x105 cells re-suspended in 100 μl of sterile PBS
ere injected into the tail veins of nude mice. Lung colonization was
onitored at day 60. The distribution of themetastasized cancer cells in
e whole lung was observed after HE staining.[
[
[
tatistical Analysis
All values are expressed as means ± SD. All data were analyzed by
paired Student's t-test for significant differences between the mean
lues of each group.
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